microbiome Archives

07 Sep Bio-Me selected as a partner in the PREVALUNG EU program developing predictive biomarkers associated with lung cancer risk

Posted at 08:52h in Uncategorized

The PREVALUNG EU program aims to implement cancer risk stratification tools and personalized interventions to intercept lung cancer in cardiovascular patients. Bio-Me’s Precision Microbiome Profiling (PMP™) was chosen for high-throughput gut microbiome profiling....

27 Apr Bio-Me’s technology used for identifying bacteria associated with appendicular lean mass in a Nature Communications publication

Posted at 08:57h in Uncategorized

PMP™ was used in a recent study to identify gut microbial species that are directly associated with appendicular lean mass and bone mineral density. More than 5000 fecal samples from the HUNT Biobank in Norway were analyzed with PMP™....

05 Aug Bio-Me´s PMP™ platform demonstrates its diagnostic and prognostic applicability in pediatric IBD

Posted at 10:23h in Uncategorized

PMP™ was used in a recent study to explore the gut microbiome of children with inflammatory bowel disease (IBD), symptomatic non-IBD, and healthy children. Diagnostic, Phenotype and Prognostic Indexes were constructed based on PMP™ data with very good discriminating properties....

04 Jul Bio-Me strengthens its international commercial team with key hire

Posted at 09:28h in Uncategorized

Bio-Me has employed Dr. Anne-Grethe Reichelt as part of the company’s plan to widen commercial adoption of their existing product portfolio and launch new products under development. ...

01 Jul Bio-Me Joins Medicen Working Group

Posted at 14:45h in Uncategorized

Bio-Me has joined the Medicen Working Group, an international initiative focusing on drug-microbiome interactions. The aim of the group is to accelerate the microbiome integration in the drug discovery and development process....

10 Jun Bio-Me´s technology demonstrates its usefulness in metabolic syndrome research in a Lancet publication

Posted at 06:02h in Uncategorized

PMP™ has shown its applicability in obesity research in a study published in The Lancet. More than 5000 fecal samples from the HUNT Biobank in Norway were analyzed with PMP™....

26 Apr Bio-Me Joins Microbiome Therapeutics Innovation Group

Posted at 09:21h in Uncategorized

Bio-Me has joined MTIG. Group members work together to accelerate microbiome-based drug development and expand availability of approved microbiome therapies to patients....

02 Mar Dr. Warren Flood steps up as CEO of Bio-Me

Posted at 10:26h in Uncategorized

Bio-Me has appointed a new CEO as part of the company’s strategic plan to be positioned as a leader in the microbiome-based Precision Medicine space....

08 Sep Joint webinar of Thermo Fisher Scientific and Bio-Me on September 22nd with focus on how the PMP™ technology can support researchers and industry

Posted at 14:43h in Uncategorized

Our COO, Warren Flood, will be participating in a webinar together with Thermo Fisher Scientific on September 22nd with a focus on our PMP™ technology and its applicability....

02 Jul Bio-Me restructures board with Gilhuus-Moe becoming Executive Chair

Posted at 11:41h in Uncategorized

Bio-Me has announced a major board restructuring that will support the Company during its new phase of development....

07 Sep Bio-Me selected as a partner in the PREVALUNG EU program developing predictive biomarkers associated with lung cancer risk

27 Apr Bio-Me’s technology used for identifying bacteria associated with appendicular lean mass in a Nature Communications publication

05 Aug Bio-Me´s PMP™ platform demonstrates its diagnostic and prognostic applicability in pediatric IBD

04 Jul Bio-Me strengthens its international commercial team with key hire

01 Jul Bio-Me Joins Medicen Working Group

10 Jun Bio-Me´s technology demonstrates its usefulness in metabolic syndrome research in a Lancet publication

26 Apr Bio-Me Joins Microbiome Therapeutics Innovation Group

02 Mar Dr. Warren Flood steps up as CEO of Bio-Me

08 Sep Joint webinar of Thermo Fisher Scientific and Bio-Me on September 22nd with focus on how the PMP™ technology can support researchers and industry

02 Jul Bio-Me restructures board with Gilhuus-Moe becoming Executive Chair

Oslo Science Park

Gaustadalléen 21

N-0349 Oslo

Norway

Tel: +47 21 09 03 02

Email:

Read Our Privacy Policy

07 Sep Bio-Me selected as a partner in the PREVALUNG EU program developing predictive biomarkers associated with lung cancer risk

27 Apr Bio-Me’s technology used for identifying bacteria associated with appendicular lean mass in a Nature Communications publication

05 Aug Bio-Me´s PMP™ platform demonstrates its diagnostic and prognostic applicability in pediatric IBD

04 Jul Bio-Me strengthens its international commercial team with key hire

01 Jul Bio-Me Joins Medicen Working Group

10 Jun Bio-Me´s technology demonstrates its usefulness in metabolic syndrome research in a Lancet publication

26 Apr Bio-Me Joins Microbiome Therapeutics Innovation Group

02 Mar Dr. Warren Flood steps up as CEO of Bio-Me

08 Sep Joint webinar of Thermo Fisher Scientific and Bio-Me on September 22nd with focus on how the PMP™ technology can support researchers and industry

02 Jul Bio-Me restructures board with Gilhuus-Moe becoming Executive Chair

Oslo Science Park

Gaustadalléen 21

N-0349 Oslo

Norway

Tel: +47 21 09 03 02

Email: info@bio-me.com

Read Our Privacy Policy

Email: